CF Foundation Awards $3.5M to Develop Antibiotic ACG-701

CF Foundation Awards $3.5M to Develop Antibiotic ACG-701

316100

CF Foundation Awards $3.5M to Develop Antibiotic ACG-701

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic fibrosis (CF). “We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to 2022 as we work closely with the Foundation to initiate clinical development for ACG-701 in CF and multiple other indications,” John Taylor, CEO of Aceragen, said in a…

You must be logged in to read/download the full post.